research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
Search
for
Sort by
Research
900-930 / 1000+ resultsresearch The manipulation of the cedrol metabolism pathway by baricitinib and its immune interaction mechanism against chemotherapy-induced alopecia
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Inhibition of 3‐methylcrotonyl‐CoA carboxylase explains the increased excretion of 3‐hydroxyisovaleric acid in valproate‐treated patients
Valproic acid treatment increases a specific acid in urine by blocking an enzyme, possibly causing skin rash and hair loss.
research FINASTERIDE (PLUS ORAL CONTRACEPTIVE PILL) VS METFORMIN IN TREATMENT OF POLYCYSTIC OVARY SYNDROME-RELATED INFERTILITY: A PROSPECTIVE RANDOMIZED TRIAL
research Simultaneous Estimation of Minoxidil and Tofacitinib Citrate in Bulk and Topical Gel - A Validated UV-spectrophotometric Technique
A reliable method was developed to measure Minoxidil and Tofacitinib in gel for hair loss treatment.
research Therapeutic Evaluation of Spironolactone and Finasteride in the Treatment of Acne Vulgaris
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research UP-03.25
Finasteride may help treat BPH by affecting certain biological markers.
research Topical tofacitinib in treatment of alopecia areata
Topical tofacitinib shows promise as a future treatment for alopecia areata.
research Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
research Anti-oxidant and Anti-inflammatory Effects of Sinapic Acid in UVB Irradiation-Damaged HaCaT Keratinocytes
Sinapic acid may protect skin cells from UV damage and reduce inflammation, making it a promising anti-aging cosmetic ingredient.
research The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
research SAT0631-HPR WHEN CAN I STOP MY STEROIDS? THE PATIENT PERSPECTIVE ON GLUCOCORTICOID USAGE IN ADULT INFLAMMATORY MYOPATHY
Patients need better information about the risks of long-term steroid use.
research Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
research Anti - inflammatory, antioxidant and antimicrobial activity of Vitex negundo and Hibiscus rosa-sinensis herbal formulation against oral pathogens
The herbal mix of hibiscus and vitex shows promise for treating autoimmune diseases due to its effectiveness and low toxicity.
research Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research TSPO ligand etifoxine attenuates LPS-induced cognitive dysfunction in mice
Etifoxine, an anxiety drug, can lessen brain inflammation and cognitive issues in mice, partly by increasing production of protective brain steroids.
research Health Canada has approved finasteride [Proscar; Merck Frosst] and doxazosin cotherapy
research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
research Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
Certain drugs that block specific enzymes can help treat prostate diseases.
research Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
Baricitinib is effective for severe alopecia areata but has some side effects.
research Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician
Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
research Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
research Passive and Iontophoretic Delivery of Three Diclofenac Salts across Various Skin Types.
Diclofenac salt delivery through skin varies based on the salt's counterions.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital
Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.